Cotadutide (MEDI0382)

Mechanism of action: GLP-1 receptor agonist; Glucagon receptor agonist; Appetite suppression; Enhanced glucose control; Increased energy expenditure

Proposed indications: Type 2 diabetes; Obesity; MASH; Fatty liver

Reported dosing range*: 100, 200, or 300 mcg once daily, subcutaneous

A 54-week Phase 2b trial randomized participants to once-daily subcutaneous doses of 100 mcg, 200 mcg, or 300 mcg (Nahra R et al. (2021). Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care).

*General range reported in available research or other sources -- not an individualized recommendation. Actual use should be supervised by a qualified provider.

Typical clinical dosing schedule: Daily dose escalation has been evaluated in clinical trials; no approved regimen exists.

Administration: Subcutaneous injection — Daily in most clinical studies

Compare with: Retatrutide (LY3437943)Survodutide (BI 456906)Pemvidutide (ALT-801)Tirzepatide

Evidence rating: ⭐⭐⭐☆☆ — Phase 2 studies have demonstrated improvements in glycemic control, body weight, and liver biomarkers.

Common side effects: Nausea, Vomiting, Diarrhea, Reduced appetite

Serious risks: Under continued evaluation in clinical development.

Monitoring: HbA1c, Weight, Liver enzymes, Renal function

Legal status: Investigational. Not FDA-approved and not available by prescription — currently accessible only through enrollment in a clinical trial.

Regulatory status: Investigational • Not FDA Approved

Contraindications: No approved labeling available.

Ambery P, et al. (2018). MEDI0382, a GLP-1/Glucagon receptor dual agonist, in overweight patients with type 2 diabetes. The Lancet (conference and subsequent publications).